View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Near-Term Downside Likely Following False Breakouts Our long-term outlook remains bullish as long as the S&P 500 remains above 5770-5850 and 5600-5670 (worst case), and we are buyers at these levels. With that said, we see potential for near-term downside as the S&P 500, Nasdaq 100 (QQQ), and FANG+ (FNGS) (1) could not decisively break out to new highs, (2) display bearish false breakouts, (3) have fallen back into their 2+ month trading ranges, (4) are violating their 1+ month uptrends, and (5...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 21, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

Bristol-Myers Squibb Company: Update to credit analysis after outlook ...

Our credit view of this issuer reflects its large scale and solid presence in the global pharmaceutical market, against its significant patent expirations.

Moody's Ratings revises Bristol's outlook to stable from negative; aff...

Moody's Ratings (Moody's) affirmed the ratings of Bristol-Myers Squibb Company ("Bristol") including the A2 senior unsecured long-term ratings, the Prime-1 commercial paper rating, the A2 rating on the senior unsecured revolving credit facility, the (P)A2 senior unsecured shelf rating, the (P)A3 sub...

Bristol-Myers Squibb Company: Key facts and statistics - LTM March 202...

A summary company profile, detailing Bristol-Myers Squibb Company’s business operations and financial highlights.

Research Team ACF
  • Research Team ACF

ACF Insight - Innovations in Oncology - the Future of Cancer Treatment...

Global oncology spending is projected to reach US$409bn by 2028E, up from US$223bn in 2023A at a 5yr CAGR of 11.5-14.5% from 2024-2028 (IQVIA, 2024). This growth is in part driven by US spending, which has increased to $99bn in 2023A up from $65bn in 2019A - the US makes up ~45% of global oncology spending.

Research Team ACF
  • Research Team ACF

Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...

Moody's assigns A2 rating to Bristol-Myers Squibb's sr. notes; outlook...

Moody's Investors Service ("Moody's") assigned an A2 rating to the new senior unsecured notes issuance of Bristol-Myers Squibb Company ("Bristol"). There are no changes to Bristol's existing ratings including the A2 senior unsecured ratings and the outlook remains unchanged at negative. Proceeds o...

Bristol-Myers Squibb Company: Update to credit analysis after confirma...

Our credit view of this issuer reflects its large scale and solid free cash flow tempered by commercial and pipeline execution risk.

Moody's confirms Bristol-Myers Squibb at A2; outlook is negative

Moody's Investors Service ("Moody's") confirmed the ratings of Bristol-Myers Squibb Company ("Bristol"). The ratings confirmed include the A2 ratings on senior unsecured bonds and a senior unsecured revolving credit facility, the (P)A2 senior unsecured shelf rating, the (P)A3 subordinated shelf rati...

Bristol-Myers Squibb Company: Update following ratings under review fo...

Our credit view of this issuer reflects its limited revenue diversity with three largest drugs driving over 60% of sales and its pipeline execution risk.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 9, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch